The continuing value of mesalazine as first-line therapy for patients with moderately active ulcerative colitis by Paridaens, K, Freddi, MJ, Travis, SPL

Modelling the benefits of an optimised treatment strategy for 5-ASA in mild-to-moderate ulcerative colitis. by Louis, E, Paridaens, K, Al Awadhi, S, Begun, J, Cheon, JH, Dignass, AU, Magro, F, Márquez, JR, Moschen, AR, Narula, N, Rydzewska, G, Freddi, MJ, Travis, SP